The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,324.00
Bid: 12,322.00
Ask: 12,326.00
Change: 206.00 (1.70%)
Spread: 4.00 (0.032%)
Open: 12,244.00
High: 12,330.00
Low: 12,228.00
Prev. Close: 12,118.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GLOBAL MARKETS-Stocks slide on surging virus cases, stimulus doubts; dollar rises

Mon, 26th Oct 2020 15:46

* Market recovery may take longer than hoped - OPEC
official

* Graphic: 2020 asset performance http://tmsnrt.rs/2yaDPgn
(Updates prices, changes comment, dateline; previous
LONDON/SYDNEY)

By Rodrigo Campos

NEW YORK, Oct 26 (Reuters) - Shares fell across the globe on
Monday as surging coronavirus cases in Europe and the United
States clouded the world economic outlook, giving the dollar a
safe-haven boost.

The United States, Russia and France set new daily records
for coronavirus infections as a resurgence of the virus swelled
across parts of the Northern Hemisphere, forcing some countries
to impose new curbs.

The spreading pandemic, along with no clear progress on a
U.S. stimulus package and caution ahead of the Nov. 3 U.S.
presidential election dragged the MSCI world equity index
down.

"The market is vulnerable to these 'bad headlines,' because
investors are generally so optimistic right now," said Willie
Delwiche, investment strategist at Baird in Milwaukee.

MSCI's gauge of stocks globally hit a record high in
September and brushed against it earlier this month.

"The market is set up for disappointment at this point,"
Delwiche said.

The Dow Jones Industrial Average fell 712.83 points,
or 2.52%, to 27,622.74, the S&P 500 lost 73.34 points, or
2.12%, to 3,392.05 and the Nasdaq Composite dropped
189.90 points, or 1.64%, to 11,358.38.

The pan-European STOXX 600 index lost 1.72% and
MSCI's gauge of stocks across the globe shed
1.69%.

Emerging market stocks lost 0.66%. MSCI's broadest index of
Asia-Pacific shares outside Japan closed 0.41%
lower, while Japan's Nikkei fell 0.09%.

Europe became the second region after Latin America to
surpass 250,000 deaths on Saturday, according to a Reuters
tally, as many European countries reported their highest number
of COVID-19 cases in a single day.

Sentiment was also hit by a survey showing German business
morale fell in October for the first time in six months.

Reports of progress in a COVID-19 vaccine being developed by
the University of Oxford and manufactured by drugmaker
AstraZeneca Plc helped limit some of the market
sell-off, analysts said.

As markets increasingly price in the likelihood of a
Democratic president and Congress which would likely result in a
rise in government spending and borrowing, U.S. 10-year Treasury
yields hit their highest since early June last week at 0.872%
.

"We have raised the probability of a Democratic sweep,
already our base case, from 40% to just over 50% and have
increased our expectation of (Democratic presidential
candidate)Biden to win from 65% to 75%," NatWest Markets
analysts said. "We see steeper U.S. yield curves and a weaker
USD as likely to prevail in our base case."

Benchmark 10-year notes last rose 13/32 in price
to yield 0.7977%, from 0.841% late on Friday.

BlackRock Inc, the world's largest asset manager, on
Monday downgraded U.S. Treasuries and upgraded their
inflation-linked peers ahead of the U.S. election.

Despite encouraging news about a COVID-19 vaccine out of
Oxford, surging coronavirus cases sent investors to the safety
of the dollar.

"Skittish investors are scooping up the greenback as virus
cases accelerate around the world, stimulus talks in Washington
remain in limbo, and trepidation is on the rise ahead of
America's presidential election," said Joe Manimbo, senior
market analyst, at Western Union Business Solutions in
Washington.

The dollar index rose 0.316%, with the euro
down 0.43% to $1.1808.

The Japanese yen weakened 0.15% versus the greenback at
104.90 per dollar, while sterling was last trading at
$1.3007, down 0.25% on the day.

In commodity markets, spot gold added 0.2% to
$1,904.46 an ounce. Silver fell 1.02% to $24.33.

Oil prices extended last week's losses. OPEC's secretary
general said an oil market recovery may take longer than hoped
as coronavirus inflections rise around the world, and OPEC and
its allies would "stay the course" in balancing the market.

U.S. crude was down 3.64% at $38.40 per barrel and
Brent was at $40.37, down 3.35% on the day.

(Reporting by Rodrigo Campos; additional reporting by Lewis
Krauskopf and Gertrude Chavez-Dreyfuss in New York, Ross Gerber
in Boston, Tom Arnold in London and Wayne Cole in Sydney;
Editing by Susan Fenton)

More News
2 Apr 2024 07:08

US FDA gives green light for use of AstraZeneca's Voydeva

(Sharecast News) - America's drug regulator gave the green light to AstraZeneca's for the add-on use of Voydeya in the treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria (PNH).

Read more
27 Mar 2024 12:02

LONDON MARKET MIDDAY: FTSE 100 underperforms ahead of US PCE data

(Alliance News) - Stock prices in London were lower at midday on Wednesday, but trade was more confident in mainland Europe, with focus turning to the release of the US Federal Reserve's preferred inflation gauge on Friday.

Read more
27 Mar 2024 11:56

C4X Discovery seeks AIM delisting but half-year revenue skyrockets

(Alliance News) - C4X Discovery Holdings PLC shares plunged on Wednesday after it said it plans to delist from AIM in London, due to "the recent downturn in the financial markets" hampering its valuation.

Read more
27 Mar 2024 09:19

AstraZeneca treatments become "first and only" to be approved in Japan

(Alliance News) - AstraZeneca PLC announced on Wednesday the approval of two of its treatments for use in Japan.

Read more
27 Mar 2024 09:03

LONDON MARKET OPEN: FTSE 100 slips as unease lingers before US data

(Alliance News) - Stock prices in London edged lower after the open on Wednesday, with some nervy trade ahead of a US inflation reading later in the week.

Read more
27 Mar 2024 08:02

LONDON BRIEFING: Diploma makes buy; Astra wins Japan drug approvals

(Alliance News) - Stocks in London opened in a muted fashion on Wednesday, with some unease lingering in equity markets ahead of a US inflation reading later in the week.

Read more
26 Mar 2024 10:18

China to speed up 'new productive forces', vice president says

BEIJING, March 26 (Reuters) - China will accelerate the development of "new productive forces" and bolster stability and security for the global economy, Vice President Han Zheng told an investment forum in Beijing, as the world's no.2 economy seeks to reassure anxious foreign firms.

Read more
25 Mar 2024 12:09

LONDON MARKET MIDDAY: Stocks make tepid start to new week

(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish.

Read more
25 Mar 2024 09:04

LONDON MARKET OPEN: FTSE 100 treads water, FTSE 250 declines

(Alliance News) - The FTSE 100 in London traded flat early Monday, while the pound remained below the USD1.26 mark, as Bank of England Governor Andrew Bailey suggested rate cuts may happen soon.

Read more
25 Mar 2024 08:40

TOP NEWS: AstraZeneca wins US approval for rare nervous system disease

(Alliance News) - AstraZeneca PLC on Monday said its Ultomiris treatment has been approved by the US Food & Drug Administration as the first and only long-acting C5 complement inhibitor to treat neuromyelitis optica spectrum disorder in adults.

Read more
25 Mar 2024 07:59

LONDON BRIEFING: AstraZeneca wins US approval, Kingfisher profit down

(Alliance News) - London's FTSE 100 is set to open lower on Monday, giving back some of last week's progress, when equities were boosted by hope of interest rate cuts.

Read more
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more
21 Mar 2024 16:43

AstraZeneca's Tagrisso successful in treating lung cancer

(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.

Read more
19 Mar 2024 08:56

TOP NEWS: AstraZeneca to buy Fusion in deal worth over USD2 billion

(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.

Read more
19 Mar 2024 07:05

AstraZeneca to buy US-listed Fusion Phrama for $2bn

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.